Telomerase-Derived Peptide GN11 Fights Kidney Fibrosis by Halting Cellular Senescence
A new hTERT-derived peptide, GN11, blocks glycolysis and cellular senescence in fibrotic kidneys via a multi-step RNA signaling cascade.
Summary
Chronic kidney disease (CKD) has no approved drugs that directly target the fibrosis driving its progression. Researchers at Lanzhou University identified GN11, an optimized peptide derived from human telomerase reverse transcriptase (hTERT), that significantly reduced kidney fibrosis in a mouse model. GN11 worked by suppressing TGF-β1/Smad3 signaling, a central driver of fibrosis, while also reducing abnormal glycolysis and cellular senescence in kidney tissue. The peptide achieved these effects through a chain of molecular events involving a long non-coding RNA, a microRNA, and the kinase Rock2. No approved anti-fibrotic drugs exist for CKD, making GN11 a notable early-stage candidate with potential relevance to other fibrotic diseases.
Detailed Summary
Chronic kidney disease affects hundreds of millions of people worldwide, and renal fibrosis — the scarring of kidney tissue — represents its final common pathway, regardless of the underlying cause. Despite this, no drug has been approved that specifically targets the fibrotic process itself. This research from Lanzhou University explores a novel therapeutic angle: repurposing a fragment of human telomerase reverse transcriptase (hTERT) as an anti-fibrotic peptide.
The researchers started with GV1001, a well-known hTERT-derived peptide previously studied in oncology, and showed it could reduce fibrosis in a unilateral ureteral obstruction (UUO) mouse model — a standard preclinical model of kidney scarring. Through systematic optimization of GV1001's structure, they developed GN11, an analog with markedly superior activity.
Phenotypic analysis revealed that GN11 effectively reduced three hallmarks of fibrotic kidney disease: aberrant glycolysis (a metabolic shift linked to fibroblast activation), cellular senescence (the accumulation of dysfunctional, inflammation-promoting cells), and apoptosis. These findings are directly relevant to aging biology, as both glycolytic reprogramming and cellular senescence are recognized drivers of age-related organ deterioration.
Mechanistically, GN11 suppressed the TGF-β1/Smad3 signaling pathway while simultaneously upregulating miR-30c-5p, a microRNA that targets and silences Rock2, a kinase implicated in fibrosis and cytoskeletal remodeling. Additionally, GN11 reduced expression of lncRNA Oip5-os1, which normally acts as a molecular sponge to neutralize miR-30c-5p — amplifying the anti-fibrotic effect. This multi-layered mechanism suggests broad potential across fibrotic diseases of different organs.
Importantly, GN11 also carries broader longevity relevance: hTERT-derived peptides intersect with telomere biology, and cellular senescence suppression is a core therapeutic target in aging research. Limitations include the exclusively preclinical and abstract-only nature of the available data.
Key Findings
- GN11, optimized from the hTERT peptide GV1001, reduced kidney fibrosis in a mouse obstruction model.
- GN11 reversed abnormal glycolysis and cellular senescence in fibrotic kidney tissue.
- The peptide suppressed TGF-β1/Smad3 signaling, a master driver of organ fibrosis.
- GN11 upregulated miR-30c-5p and reduced lncRNA Oip5-os1, jointly silencing the pro-fibrotic kinase Rock2.
- No clinically approved drugs currently target renal fibrosis; GN11 represents a novel candidate.
Methodology
Researchers used a unilateral ureteral obstruction (UUO) mouse model to induce renal fibrosis and tested both GV1001 and the optimized peptide GN11. Phenotypic outcomes included glycolysis, cellular senescence, and apoptosis markers; mechanistic studies examined TGF-β1/Smad3 signaling and the lncRNA/miRNA/Rock2 axis. The study is preclinical; no human or clinical trial data are presented.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. All data are preclinical (mouse UUO model), and GN11 has not been tested in humans. The peptide's pharmacokinetics, bioavailability, toxicity profile, and clinical translation potential remain unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: